Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Recipharm publ AB (0QSD)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Recipharm publ AB historical data, for real-time data please try another search
232.40 0.00    0.00%
05/03 - Closed. Currency in SEK ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  SE0005757267 
SEDOL:  BLRZLJ0
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 232.40 - 232.40
Recipharm publ AB 232.40 0.00 0.00%

Recipharm AB (publ) Company Profile

 
Get an in-depth profile of Recipharm publ AB, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

DRC

Recipharm AB (publ) operates as a pharmaceutical contract development and manufacturing company in Sweden, the United Kingdom, Italy, Germany, France, India, Spain, Portugal, and internationally. It operates through four segments: Advanced Delivery Systems (ADS), Manufacturing Steriles (MFG-S), Manufacturing Solids & Others (MFG-SO), and Development & Licensing (D&L). The ADS segment develops and manufactures inhalation products and devices, including integrated drug solutions, medical check valves, and injection devices. The MFG-S segment manufactures sterile products using lyophilisation and blow-fillseal technologies. The MFG-SO segment manufactures non-sterile products, such as tablets, capsules, semi-solids, liquids, and powders. The D&L segment provides pharmaceutical development services, including preclinical and formulation development, and clinical trial material services; manages patents, technologies, and drug product rights; and develops and manufactures drug substance. It also offers packaging products comprising bottles, blisters, stick-packs, vials, ampoules, syringes, pouches, and patches; and online vendor managed inventory solutions. The company was founded in 1994 and is headquartered in Stockholm, Sweden.

Contact Information

Address Drottninggatan 29 PO Box 603
Stockholm, 101 32
Sweden
Phone 46 86 02 52 00
Fax -
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RECIb Comments

Write your thoughts about Recipharm AB (publ)
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email